AMGN
AmgenstockAMGN · 90-day price history
Prediction models
All predictions →Trend follower
Horizon: 1 week
How this worksHide explanation
Compares a 10-day vs 50-day moving average. When the short-term average rises above the long-term average, the trend is up.
Not financial advice. Past accuracy does not guarantee future results.
Momentum
Horizon: 1 week
How this worksHide explanation
Uses RSI (a gauge of recent buying/selling intensity) and 5-day rate-of-change to judge whether the stock has been pushed too far in one direction.
Not financial advice. Past accuracy does not guarantee future results.
Statistical trend
Horizon: 1 month
How this worksHide explanation
Fits a trend line through the last 60 days of prices and measures how far the current price has strayed from it.
Not financial advice. Past accuracy does not guarantee future results.
Multi-factor + news
Horizon: 1 week
Accuracy data accumulates as predictions are evaluated over time.
How this worksHide explanation
Combines trend (25%), momentum (25%), volume (15%), and AI-analysed news sentiment (35%) from your trusted sources into one score.
Not financial advice. Past accuracy does not guarantee future results.
Bull / Bear thesis
AI analysisMultiple growth drivers across pipeline
Amgen highlights 26% growth drivers, IMDELLTRA momentum in specific indication, and MariTide potential as next-gen therapies
YahooProfitable with growing dividend outperforms speculative peers
Compared to Revolution Medicines and CRISPR, Amgen's profitability and dividends provide stability vs. cash-burning competitors
YahooEstablished commercial infrastructure optimizes launches
Amgen's IMDELLTRA momentum benefits from world-class sales and marketing capabilities
YahooStock decline despite positive growth narrative
Down 2.25% despite growth driver announcements, suggesting market skepticism
Price actionPremium valuation limits upside on execution
At $382, stock trades at levels reflecting strong expectations
Price actionCompetition from GLP-1 players and others
Broader biotech competition potentially limiting share gains for Amgen products
Price actionAI-generated from recent news and price action. Not financial advice. Educational only.
Seasonality
~5y of historyAvg return by month · %
This month historically: -3.15% on average, up 20% of 5 years.
Avg return by weekday · %
Historical pattern only — seasonality is not a prediction and often breaks.
Recent news
Yahoo · Sep 11
Amgen's 26% growth drivers across commercial products and pipeline demonstrate multiple paths to revenue expansion beyond any single franchise.
Yahoo · Sep 11
Amgen's profitability, dividends, and free cash flow generation provide a stark contrast to Revolution's cash burn, appealing to different investor profiles.
Yahoo · Sep 11
Amgen's established revenue, profitability and dividend provide income while CRISPR bets on a potential breakthrough, reflecting different risk/reward profiles.
AI research companion
AI Research Companion
Loading…
Ready to paper trade AMGN?
Switch to Portfolio mode to buy and sell with $100k of simulated funds.